Literature DB >> 26476344

Blood, urine and faecal metabolite profiles in the study of adult renal disease.

Clara Barrios1, Tim D Spector2, Cristina Menni3.   

Abstract

Chronic kidney disease (CKD) is a major public health burden and to date traditional biomarkers of renal function (such as serum creatinine and cystatin C) are unable to identify at-risk individuals before the disease process is well under way. To help preventive strategies and maximize the potential for effective interventions, it is important to characterise the molecular changes that take place in the development of renal damage. Metabolomics is a promising tool to identify markers of renal disease since the kidneys are involved in the handling of major biochemical classes of metabolites. These metabolite levels capture a snap-shot of the metabolic profile of the individual, allowing for the potential identification of early biomarkers, and the monitoring of real-time kidney function. In this review, we describe the current status of the identification of blood/urine/faecal metabolic biomarkers in different entities of kidney diseases including: acute kidney injury, chronic kidney disease, renal transplant, diabetic nephropathy and other disorders.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Biomarkers; Chronic kidney disease; Metabolomics; Renal disorders

Mesh:

Year:  2015        PMID: 26476344     DOI: 10.1016/j.abb.2015.10.006

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  16 in total

Review 1.  The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.

Authors:  David Briskey; Patrick Tucker; David W Johnson; Jeff S Coombes
Journal:  Clin Exp Nephrol       Date:  2016-03-10       Impact factor: 2.801

2.  Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction.

Authors:  Junju Zou; Xiaotao Zhou; Xian Chen; Yuerong Ma; Rong Yu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

3.  Fecal Metabolomics Reveals Distinct Profiles of Kidney Transplant Recipients and Healthy Controls.

Authors:  Soumaya Kouidhi; Oumaima Zidi; Muhanad Alhujaily; Nessrine Souai; Amor Mosbah; Tareg M Belali; Kais Ghedira; Imene El Kossai; Jamelddine El Manaa; Wissem Mnif; Ameur Cherif
Journal:  Diagnostics (Basel)       Date:  2021-04-29

Review 4.  Metabolomic Profiling for Diagnosis and Prognostication in Surgery: A Scoping Review.

Authors:  Tabassum A Khan; Tyler J Loftus; Amanda C Filiberto; Tezcan Ozrazgat-Baslanti; Matthew M Ruppert; Sabyasachi Bandyopadhyay; Evagelia C Laiakis; Dean J Arnaoutakis; Azra Bihorac
Journal:  Ann Surg       Date:  2021-02-01       Impact factor: 13.787

5.  Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations.

Authors:  Clara Barrios; Jonas Zierer; Peter Würtz; Toomas Haller; Andres Metspalu; Christian Gieger; Barbara Thorand; Christa Meisinger; Melanie Waldenberger; Olli Raitakari; Terho Lehtimäki; Sol Otero; Eva Rodríguez; Juan Pedro-Botet; Mika Kähönen; Mika Ala-Korpela; Gabi Kastenmüller; Tim D Spector; Julio Pascual; Cristina Menni
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

6.  Metabolomics and Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire.

Authors:  Rachel S Kelly; Adrianna Boulin; Nancy Laranjo; Kathleen Lee-Sarwar; Su H Chu; Aishwarya P Yadama; Vincent Carey; Augusto A Litonjua; Jessica Lasky-Su; Scott T Weiss
Journal:  Metabolites       Date:  2019-03-05

7.  Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine, Methionine, and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis.

Authors:  Marius A Øvrehus; Per Bruheim; Wenjun Ju; Leila R Zelnick; Knut A Langlo; Kumar Sharma; Ian H de Boer; Stein I Hallan
Journal:  Kidney Int Rep       Date:  2018-10-17

8.  A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.

Authors:  Skander Mulder; Ann Hammarstedt; Sunil B Nagaraj; Viji Nair; Wenjun Ju; Jonatan Hedberg; Peter J Greasley; Jan W Eriksson; Jan Oscarsson; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2020-03-25       Impact factor: 6.577

9.  Blood and urinary metabolomic evidence validating traditional Chinese medicine diagnostic classification of major depressive disorder.

Authors:  Lan-Ying Liu; Hong-Jian Zhang; Li-Yuan Luo; Jin-Bao Pu; Wei-Qing Liang; Chun-Qin Zhu; Ya-Ping Li; Pei-Rong Wang; Yuan-Yuan Zhang; Chun-Yu Yang; Zhang-Jin Zhang
Journal:  Chin Med       Date:  2018-10-25       Impact factor: 5.455

10.  The metabolomic quest for a biomarker in chronic kidney disease.

Authors:  Robert Davies
Journal:  Clin Kidney J       Date:  2018-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.